Autoimmune Diseases News and Research RSS Feed - Autoimmune Diseases News and Research

Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Penn researchers find molecular bond between DNA damage, cellular senescence and premature aging

Like a beloved pair of jeans, human DNA accumulates damage over time, and older people's bodies can't repair it as well. Many scientists believe a build up of damage can cause cells to enter an irreversible dormant state known as senescence. Cellular senescence is believed to be responsible for some of the telltale signs of aging, such as weakened bones, less resilient skin and slow-downs in organ function. [More]
Scientists identify missing genetic link in common variable immunodeficiency disorder

Scientists identify missing genetic link in common variable immunodeficiency disorder

In the largest genetic study to date of a challenging immunodeficiency disorder, scientists have identified a gene that may be a "missing link" between overactive and underactive immune activity. The gene candidate also plays a key role in autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and allergies. [More]
University of Birmingham researchers identify new way to tackle chronic diseases

University of Birmingham researchers identify new way to tackle chronic diseases

Researchers from the University of Birmingham have identified an important new way in which our immune systems are regulated, and hope that understanding it will help tackle the debilitating effects of type 1 diabetes, rheumatoid arthritis and other serious diseases. [More]
Latest genome sequencing techniques help identify new autoimmune syndrome in children

Latest genome sequencing techniques help identify new autoimmune syndrome in children

Using the latest genome sequencing techniques, a research team led by scientists from UC San Francisco, Baylor College of Medicine, and Texas Children's Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy. [More]
Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA. [More]
Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. [More]
Researchers reveal the precise mechanism used by bacteria to target invading viruses

Researchers reveal the precise mechanism used by bacteria to target invading viruses

One of the immune system's most critical challenges is to differentiate between itself and foreign invaders -- and the number of recognized autoimmune diseases, in which the body attacks itself, is on the rise. [More]
UAB research findings may lead to better treatment for women with HER2+ breast cancer

UAB research findings may lead to better treatment for women with HER2+ breast cancer

There are five subtypes of breast cancer, and they are distinct diseases with vastly different biologies that drastically alter their progression and responses to treatment. Understanding those differences is the starting point to a more effective, personalized treatment of breast cancer, which strikes more than 230,000 women in the U.S. each year. [More]
Inova Diagnostics gains FDA de novo clearance for NOVA View automated digital IFA microscope

Inova Diagnostics gains FDA de novo clearance for NOVA View automated digital IFA microscope

Inova Diagnostics, the worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, announced today that the United States Food and Drug Administration has cleared NOVA View, an automated digital IFA (indirect fluorescent assay) microscope, through the de novo classification process. [More]
Juvenile arthritis care in NSW, Australia: an interview with Jannine Jackson

Juvenile arthritis care in NSW, Australia: an interview with Jannine Jackson

Juvenile arthritis is a disease that, by definition, affects children under the age of sixteen. It's an autoimmune inflammatory condition that affects children's joints. Several different forms of the condition are diagnosed based on how many joints are affected and whether or not other parts of the body are also affected... [More]
Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Bariatric surgery prior to joint replacement improves outcomes in obese patients

Bariatric surgery prior to joint replacement improves outcomes in obese patients

Obesity is not only a risk factor for developing knee and hip arthritis. It is also linked to less favorable outcomes after joint replacement surgery. [More]
Autoimmune disease forum to be held in Tampa on March 28, 2015

Autoimmune disease forum to be held in Tampa on March 28, 2015

The "What Every American Needs to Know About Autoimmune Disease" public forum arrives in Tampa on Saturday, March 28th. The program will begin at 9:30am and end at 3:30pm. [More]
Lycera achieves milestone in Merck research collaboration

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. [More]
HSS study examines racial and socioeconomic disparities in hip fracture care

HSS study examines racial and socioeconomic disparities in hip fracture care

A study by researchers at Hospital for Special Surgery (HSS) finds that people in certain racial and socioeconomic groups are at a disadvantage when it comes to care they receive after fracturing a hip. [More]
Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement is often performed in patients with juvenile arthritis when their joints have been severely damaged by the disease. [More]
TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015. [More]
Scientists identify key molecules that trigger immune system to fight tularemia

Scientists identify key molecules that trigger immune system to fight tularemia

Research led by scientists at St. Jude Children's Research Hospital has identified key molecules that trigger the immune system to launch an attack on the bacterium that causes tularemia. [More]
Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis. [More]
Advertisement
Advertisement